|
1
|
Libby P and Theroux P: Pathophysiology of
coronary artery disease. Circulation. 111:3481–3488. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Williams KJ and Tabas I: Atherosclerosis
and inflammation. Science. 297:521–522. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ross R: Atherosclerosis-an inflammatory
disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tabas I: Macrophage death and defective
inflammation resolution in atherosclerosis. Nat Rev Immunol.
10:36–46. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hansson GK and Libby P: The immune
response in atherosclerosis: A double-edged sword. Nat Rev Immunol.
6:508–519. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hansson GK and Hermansson A: The immune
system in atherosclerosis. Nat Immunol. 12:204–212. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghildiyal M and Zamore PD: Small silencing
RNAs: An expanding universe. Nat Rev Genet. 10:94–108. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soifer HS, Rossi JJ and Saetrom P:
MicroRNAs in disease and potential therapeutic applications. Mol
Ther. 15:2070–2079. 2017. View Article : Google Scholar
|
|
11
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Connell RM, Rao DS, Chaudhuri AA and
Baltimore D: Physiological and pathological roles for microRNAs in
the immune system. Nat Rev Immunol. 10:111–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hosin AA, Prasad A, Viiri LE, Davies AH
and Shalhoub J: MicroRNAs in atherosclerosis. J Vasc Res.
51:338–3349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang LP, Wang JP and Wang XP: HOTAIR
contributes to the growth of liver cancer via targeting miR-217.
Oncol Lett. 15:7963–7972. 2018.PubMed/NCBI
|
|
16
|
Safaralizadeh R, Ajami N, Nemati M,
Hosseinpourfeizi M, Azimzadeh Isfanjani A and Moaddab SY:
Dysregulation of miR-216a and miR-217 in gastric cancer and their
clinical significance. J Gastrointest Cancer. 50:78–83. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu AN, Qu HJ, Yu CY and Sun P: Knockdown
of LINC01614 inhibits lung adenocarcinoma cell progression by
upregulating miR-217 and downregulating FOXP1. J Cell Mol Med.
22:4034–4044. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan J, Wu G, Chen J, Xiong L, Chen G and
Li P: Downregulated miR-217 expression predicts a poor outcome in
acute myeloid leukemia. Cancer Biomark. 22:73–78. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu H, Li X, Song Y and Wang Z:
MicroRNA-217 attenuates intima-media complex thickness of ascending
aorta measured by ultrasound bio-microscopy and inhibits
inflammation and lipid metabolism in atherosclerotic models of
ApoE−/− mice. Lipids Health Dis. 17:1702018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu K, Xuekelati S, Zhou K, Yan Z, Yang X,
Inayat A, Wu J and Guo X: Expression profiles of six
atherosclerosis-associated microRNAs that cluster in patients with
hyperhomocysteinemia: A clinical study. DNA Cell Biol. 37:189–198.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nogueiras R, Habegger KM, Chaudhary N,
Finan B, Banks AS, Dietrich MO, Horvath TL, Sinclair DA, Pfluger PT
and Tschöp MH: Sirtuin 1 and sirtuin 3: Physiological modulators of
metabolism. Physiol Rev. 92:1479–1514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
da Cunha MSB and Arruda SF:
Tucum-do-Cerrado (Bactris setosa Mart.) may promote anti-aging
effect by upregulating SIRT1-Nrf2 pathway and attenuating oxidative
stress and inflammation. Nutrients. 9(pii): E12432017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rada P, Pardo V, Mobasher MA,
García-Martínez I, Ruiz L, González-Rodríguez Á, Sanchez-Ramos C,
Muntané J, Alemany S, James LP, et al: SIRT1 controls acetaminophen
hepatotoxicity by modulating inflammation and oxidative stress.
Antioxid Redox Signal. 28:1187–1208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan SH, Hung CH, Shih JY, Chu PM, Cheng
YH, Lin HC and Tsai KL: SIRT1 inhibition causes oxidative stress
and inflammation in patients with coronary artery disease. Redox
Biol. 13:301–309. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng YY, Kao CL, Ma HI, Hung CH, Wang CT,
Liu DH, Chen PY and Tsai KL: SIRT1-related inhibition of
pro-inflammatory responses and oxidative stress are involved in the
mechanism of nonspecific low back pain relief after exercise
through modulation of Toll-like receptor 4. J Biochem. 158:299–308.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang X, Wei J, He Y, Jing T, Li Y, Xiao Y,
Wang B, Wang W, Zhang J and Lin R: SIRT1 inhibition promotes
atherosclerosis through impaired autophagy. Oncotarget.
8:51447–51461. 2017.PubMed/NCBI
|
|
27
|
Ross R: Atherosclerosis-an inflammatory
disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagy L, Tontonoz P, Alvarez JG, Chen H and
Evans RM: Oxidized LDL regulates macrophage gene expression through
ligand activation of PPARgamma. Cell. 93:229–240. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han Y, Ma J, Wang J and Wang L: Silencing
of H19 inhibits the adipogenesis and inflammation response in
ox-LDL-treatedRaw264.7 cells by up-regulating miR-130b. Mol
Immunol. 93:107–114. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsui L and Wang IJ: Analysis and
quantification of oxidized low-density lipoprotein-induced lipid
droplets in macrophages through high-content screening: Application
for antiatherogenic drugs discovery. Assay Drug Dev Technol.
17:223–230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Du XJ, Lu JM and Sha Y: MiR-181a inhibits
vascular inflammation induced by ox-LDL via targeting TLR4 in human
macrophages. J Cell Physiol. 233:6996–7003. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Herrington W, Lacey B, Sherliker P,
Armitage J and Lewington S: Epidemiology of atherosclerosis and the
potential to reduce the global burden of atherothrombotic disease.
Circ Res. 118:535–546. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hansson GK: Inflammation, atherosclerosis,
and coronary artery disease. N Engl J Med. 352:1685–1695. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ryo A, Suizu F, Yoshida Y, Perrem K, Liou
YC, Wulf G, Rottapel R, Yamaoka S and Lu KP: Regulation of
NF-kappaB signaling by Pin1-dependent prolyl isomerization and
ubiquitin-mediated proteolysis of p65/RelA. Mol Cell. 12:1413–1426.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Imanishi T and Akasaka T: Novel strategies
to target inflammatory processes in atherosclerosis. Curr Pharm
Design. 19:1616–1625. 2013. View Article : Google Scholar
|
|
37
|
Li P, Zhong X, Li J, Liu H, Ma X, He R and
Zhao Y: MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated
endothelial cell pyroptosis through FOXO3 down-regulation in
atherosclerosis. Biochem Biophys Res Commun. 503:2833–2844. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei Y, Nazari-Jahantigh M, Chan L, Zhu M,
Heyll K, Corbalán-Campos J, Hartmann P, Thiemann A, Weber C and
Schober A: The microRNA-342-5p fosters inflammatory macrophage
activation through an Akt1- and microRNA-155-dependent pathway
during atherosclerosis. Circulation. 127:1609–1619. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zernecke A, Bidzhekov K, Noels H,
Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh
MN, Lutgens E, et al: Delivery of microRNA-126 by apoptotic bodies
induces CXCL12-dependent vascular protection. Sci Signal.
2:ra812009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Y, Liu D, Chen X, Li J, Li L, Bian
Z, Sun F, Lu J, Yin Y, Cai X, et al: Secreted monocytic miR-150
enhances targeted endothelial cell migration. Mol Cell. 39:133–144.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nazari-Jahantigh M, Wei Y, Noels H, Akhtar
S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, et
al: MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in
macrophages. J Clin Invest. 122:4190–4202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qin B, Shu Y, Long L, Li H, Men X, Feng L,
Yang H and Lu Z: MicroRNA-142-3p induces atherosclerosis-associated
endothelial cell apoptosis by directly targeting rictor. Cell
Physiol Biochem. 47:1589–1603. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu Y, Xin D, Liu C and Wang F: SIRT1
participates in epithelial-mesenchymal transition of EC-9706 and
Eca-109 cells in vitro by regulating Snail expression. Nan Fang Yi
Ke Da Xue Xue Bao. 38:1325–1330. 2018.(In Chinese). PubMed/NCBI
|
|
44
|
Tian Y, Ma J, Wang W, Zhang L, Xu J, Wang
K and Li D: Resveratrol supplement inhibited the NF-κB inflammation
pathway through activating AMPKα-SIRT1 pathway in mice with fatty
liver. Mol Cell Biochem. 422:75–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jung CH, Lee MJ, Kang YM, Lee YL, Seol SM,
Yoon HK, Kang SW, Lee WJ and Park JY: C1q/TNF-related protein-9
inhibits cytokine-induced vascular inflammation and leukocyte
adhesiveness via AMP-activated protein kinase activation in
endothelial cells. Mol Cell Endocrinol. 419:235–243. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zabielska MA, Borkowski T, Slominska EM
and Smolenski RT: Inhibition of AMP deaminase as therapeutic target
in cardiovascular pathology. Pharmacol Rep. 67:682–688. 2015.
View Article : Google Scholar : PubMed/NCBI
|
